Trial

Building Evidence for Advancing New Treatment for Rifampicin Resistant Tubercuosis

Study Director
Dr. Francesca Conradie
Start Date
8 / 2019
Trial Phase
Phase III
Trial Status
enrolling
Current Enrollment
120 October 2020
Target Enrollment
400
Overview

6 mo BDQ DLM LZD LVX CFZ

Regimen Associations